US 6,489,345 B1Grant

Treatment of diabetes and related pathologies

Issue Date:2002-12-03

•20 Claims

Abstract

Methods for treating diabetes mellitus and related conditions and symptoms are described. The methods are directed to administering a therapeutically effective amount of a compound. Compounds suitable for the invention include pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, pyridoxine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof. Also disclosed are methods directed to concurrently administering a therapeutically effective amount of a compound with other compounds known in the treatment of diabetes mellitus. In one embodiment, a therapeutically effective amount of a compound is administered concurrently with a therapeutically effective amount of insulin. In another embodiment, a therapeutically effective amount of a compound is administered concurrently with a therapeutically effective amount of a hypoglycemic compound.

Metadata

Assignee

Medicure, Inc.

Inventors

Rajat Sethi
Wasimul Haque

Application Information

Application Number:US 09/615,201

Filing Date:2000-07-13

Priority Date:1999-07-13

Art Unit:7

Classifications

IPC:

A61K 3144

Field of Search:

514332514866

Patent Drawings

This patent does not have any drawings.

Description

[0002] This application claims priority to provisional application Ser. No. 60/143,466, filed on Jul. 13, 1999.

FIELD OF THE INVENTION

[0003] This invention relates to methods of treating insulin-dependent diabetes mellitus, noninsulin-dependent diabetes mellitus, and related conditions and symptoms.

BACKGROUND

[0004] Diabetes mellitus is a condition in which blood glucose levels are abnormally high because the body is unable to produce enough insulin to maintain normal blood glucose levels or is unable to adequately respond to the insulin produced. Insulin-dependent diabetes mellitus (often referred to as type I diabetes) arises when the body produces little or no insulin. About 10% of all diabetics have type I diabetes. Noninsulin-dependent diabetes mellitus (often referred to as type II diabetes) arises when the body cannot adequately respond to the insulin that is produced in response to blood glucose levels. Type II diabetes is often associated with hyperglycemia (high plasma glucose levels due to decreased glucose utilization) and hyperinsulinemia (high plasma insulin levels due to decreased insulin receptors available), factors that contribute to insulin resistance.

[0005] Available treatments include weight control, exercise, diet, and drug therapy. Drug therapy for type I diabetes mellitus requires the administration of insulin; however, drug therapy for type II diabetes mellitus usually involves the administration of insulin and/or oral hypoglycemic drugs to lower blood glucose levels. If the oral hypoglycemic drugs fail to control blood sugar, then insulin, either alone or in combination with the hypoglycemic drugs, will usually be administered.

[0006] Although many of the symptoms of diabetes mellitus may be controlled by insulin therapy, the long-term complications of both type I and type II diabetes mellitus are severe and may reduce life expectancy by as much as one third. Over time, elevated blood glucose levels damage blood vessels, eyes, kidneys, nerves, autonomic nervous system, skin, connective tissue, and white blood cell function.

[0007] Moreover, insulin therapy may result in insulin allergy, insulin resistance, atrophy of the subcutaneous fat at the site of insulin injection (i.e., lipoatrophy), enlargement of subcutaneous fat deposit (i.e., lipohypertrophy) due to lipogenic action of high local concentration of insulin, and insulin adema.

[0008] Thus, it would be desirable to find an alternative to the above-described therapies or to administer a drug therapy that may reduce the amount of insulin or hypoglycemic drug required, yet maintain the effectiveness of the insulin or hypoglycemic drug administered.

SUMMARY OF THE INVENTION

[0009] The present invention provides methods for treating insulin-dependent diabetes mellitus, noninsulin-dependent diabetes mellitus, and related conditions and symptoms. One embodiment includes a method of treating diabetes mellitus in a mammal by administering a therapeutically effective amount of a compound, such as pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, pyridoxine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof.

[0010] In another embodiment, the invention provides a method of treating diabetes mellitus in a mammal by concurrently administering a therapeutically effective amount of a combination of insulin and a compound, such as pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, pyridoxine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof.

[0011] In still another embodiment, the invention provides a method of treating noninsulin-dependent diabetes mellitus in a mammal by concurrently administering a therapeutically effective amount of a combination of a hypoglycemic compound and a compound, such as pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, pyridoxine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof.

DETAILED DESCRIPTION

[0012] The present invention provides methods for treatment of diabetes mellitus and related conditions and symptoms. Such diabetes mellitus and related conditions include insulin-dependent diabetes mellitus (type I diabetes), noninsulin-dependent diabetes mellitus (type II diabetes), insulin resistance, hyperinsulinemia, and diabetes-induced hypertension. Other diabetes-related conditions include obesity and damage to blood vessels, eyes, kidneys, nerves, autonomic nervous system, skin, connective tissue, and immune system.

[0013] In accordance with the present invention, it has been found that compounds, such as, for example, pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof, either alone or in combination with insulin and/or hypoglycemic compounds can be used in the treatment of the above-identified diseases and conditions. As used herein, “treatment” and “treating” include preventing, inhibiting, and alleviating diabetes mellitus and related conditions and symptoms. In some instances, the treatment may be carried out by administering a therapeutically effective amount of a compound suitable for use in methods of the invention. In other instances, the treatment may be carried out by concurrently administering a therapeutically effective amount of a combination of insulin and a compound suitable for use in methods of the invention. In still other instances, the treatment may involve concurrently administering a therapeutically effective amount of a combination of a hypoglycemic compound and a compound suitable for use in methods of the invention when the diabetes mellitus and related conditions to be treated is type II diabetes, insulin resistance, hyperinsulinemia, diabetes-induced hypertension, obesity, or damage to blood vessels, eyes, kidneys, nerves, autonomic nervous system, skin, connective tissue, or immune system.

[0014] A “therapeutically effective amount” as used herein includes a prophylactic amount, for example, an amount effective for preventing or protecting against diabetes mellitus and related conditions and symptoms, and amounts effective for alleviating or healing diabetes mellitus and related conditions and symptoms. Generally, by a administering a compound suitable for use in methods of the invention concurrently with insulin and/or a hypoglycemic compound the insulin and/or hypoglycemic compound may be administered in a dosage amount that is less than the dosage amount required when the insulin and/or hypoglycemic compound is the sole active ingredient. By administering lower dosage amounts of insulin and/or a hypoglycemic compound, the side effects associated therewith should accordingly be reduced and/or the onset of the long-term complications that arise from diabetes mellitus and related conditions may be delayed.

[0015] Compounds suitable for use in the methods of the invention include pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, pyridoxine, 3-acylated pyridoxal analogues, pharmaceutically acceptable acid addition salts thereof, or a mixture thereof. 3-Acylated pyridoxal analogues include prodrugs of pyridoxal that provide for slower metabolism to pyridoxal in vivo. For example, one suitable 3-acylated analogue of pyridoxal (2-methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine) is a compound of the formula I:

[0016] or a pharmaceutically acceptable acid addition salt thereof, wherein

[0017] R₁is a straight or branched alkyl group, a straight or branched alkenyl group, in which an alkyl or alkenyl group may be interrupted by a nitrogen or oxygen atom; an alkoxy group; a dialkylamino group; or an unsubstituted or substituted aryl group.

[0018] The term “alkyl” group includes a straight or branched saturated aliphatic hydrocarbon chain having from 1 to 8 carbon atoms, such as, for example, methyl, ethyl, propyl, isopropyl (1-methylethyl), butyl, tert-butyl (1,1-dimethylethyl), and the like.

[0019] The term “alkenyl” group includes an unsaturated aliphatic hydrocarbon chain having from 2 to 8 carbon atoms, such as, for example, ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-methyl- 1-propenyl, and the like.

[0020] The above alkyl or alkenyl groups may optionally be interrupted in the chain by a heteroatom, such as, for example, a nitrogen or oxygen atom, forming an alkylaminoalkyl or alkoxyalkyl group, for example, methylaminoethyl or methoxymethyl, and the like.

[0021] The term “alkoxy” group includes an alkyl group as defined above joined to an oxygen atom having preferably from 1 to 4 carbon atoms in a straight or branched chain, such as, for example, methoxy, ethoxy, propoxy, isopropoxy (1-methylethoxy), butoxy, tert-butoxy (1,1-dimethylethoxy), and the like.

[0022] The term “dialkylamino” group includes two alkyl groups as defined above joined to a nitrogen atom, in which the alkyl group has preferably 1 to 4 carbon atoms, such as, for example, dimethylamino, diethylamino, methylethylamino, methylpropylamino, diethylamino, and the like.

[0023] The term “aryl” group includes an aromatic hydrocarbon group, including fused aromatic rings, such as, for example, phenyl and naphthyl. Such groups may be unsubstituted or substituted on the aromatic ring by, for example, an alkyl group of 1 to 4 carbon atoms, an alkoxy group of 1 to 4 carbon atoms, an amino group, a hydroxy group, or an acetyloxy group.

[0024] Preferred R₁groups for compounds of formula I are toluyl or naphthyl. Such R₁groups when joined with a carbonyl group form an acyl group

[0025] which preferred for compounds of formula I include toluoyl or β-naphthoyl. Of the toluoyl group, the p-isomer is more preferred.

[0026] Examples of 3-acylated analogues of pyridoxal include, but are not limited to, 2-methyl-3-toluoyloxy-4-formyl-5-hydroxymethylpyridine and 2-methyl-β-naphthoyloxy-4-formyl-5-hydroxymethylpyridine.

[0027] Another suitable analogue is a 3-acylated analogue of pyridoxal-4,5-aminal (1-secondary amino-1,3-dihydro-7-hydroxy-6-methylfuro(3,4-c)pyridine) of the formula II:

[0028] or a pharmaceutically acceptable acid addition salt thereof, wherein

[0029] R₁is a straight or branched alkyl group, a straight or branched alkenyl group, in which an alkyl or alkenyl group may be interrupted by a nitrogen or oxygen atom; an alkoxy group; a dialkylamino group; or an unsubstituted or substituted aryl group; and

[0030] R₂is a secondary amino group.

[0031] The terms “alkyl,” “alkenyl,” “alkoxy,” “dialkylamino,” and “aryl” are as defined above.

[0032] The term “secondary amino” group includes a group of the formula III:

[0033] derived from a secondary amine R₃R₄NH, in which R₃and R₄are each independently alkyl, alkenyl, cycloalkyl, aryl, or, when R₃and R₄are taken together, may form a ring with the nitrogen atom and which may optionally be interrupted by a heteroatom, such as, for example, a nitrogen or oxygen atom. The terms “alkyl,” “alkenyl,” and “aryl” are used as defined above in forming secondary amino groups such as, for example, dimethylamino, methylethylamino, diethylamino, dialkylamino, phenylmethylamino, diphenylamino, and the like.

[0034] The term “cycloalkyl” refers to a saturated hydrocarbon having from 3 to 8 carbon atoms, preferably 3 to 6 carbon atoms, such as, for example, cyclopropyl, cyclopentyl, cyclohexyl, and the like.

[0035] When R₃and R₄are taken together with the nitrogen atom, they may form a cyclic secondary amino group, such as, for example, piperidino, and, when interrupted with a heteroatom, includes, for example, piperazino and morpholino.

[0036] Preferred R₁groups for compounds of formula II include toluyl, e.g., p-toluyl, naphthyl, tert-butyl, dimethylamino, acetylphenyl, hydroxyphenyl, or alkoxy, e.g., methoxy. Such R₁groups when joined with a carbonyl group form an acyl group

[0037] which preferred for compounds and formula II include toluoyl, β-naphthoyl, pivaloyl, dimethylcarbamoyl, acetylsalicyloyl, salicyloyl, or alkoxycarbonyl. A preferred secondary amino group may be morpholino.

[0038] Examples of 3-acylated analogues of pyridoxal-4,5-aminal include, but are not limited to, 1-morpholino-1,3-dihydro-7-(p-toluoyloxy)-6-methylfuro(3,4-c)pyridine; 1-morpholino-1,3-dihydro-7-(naphthoyloxy)-6-methylfuro(3,4-c)pyridine; 1-morpholino-1,3-dihydro-7-pivaloyloxy-6-methylfuro(3,4-c)pyridine; 1-morpholino-1,3-dihydro-7-carbamoyloxy-6-methylfuro(3,4-c)pyridine; and 1-morpholino-1,3-dihydro-acetylsalicyloxy-6-methylfuro(3,4-c)pyridine.

[0039] The compounds of formula I may be prepared by reacting pyridoxal hydrochloride with an acyl halide in an aprotic solvent. A suitable acyl group is

[0040] wherein R₁is as defined above. A particularly suitable acyl halide includes p-toluoyl chloride or β-naphthoyl chloride. A suitable aprotic solvent includes acetone, methylethylketone, and the like.

[0041] The compounds of formula II may be prepared by reacting 1-secondary amino-1,3-dihydro-7-hydroxy-6-methylfuro(3,4-c)pyridine with an acyl halide in an aprotic solvent. An acyl group is

[0042] wherein R₁is as defined above. A particularly suitable acyl halide includes p-toluoyl chloride, β-naphthoyl chloride, trimethylacetyl chloride, dimethylcarbamoyl chloride, and acetylsalicyloyl chloride. A particularly suitable secondary amino group includes morpholino.

[0043] The compound 1-morpholino-1,3-dihydro-7-hydroxy-6-methylfuro(3,4-c)pyridine may be prepared by methods known in the art, for example, by reacting morpholine and pyridoxal hydrochloride at a temperature of about 100° C. in a solvent. A suitable solvent includes, for example, toluene. Similarly, other secondary amines as defined for R₂may be used as reactants to prepare the appropriate 1-secondary amino compounds.

[0044] The compounds of formula I may alternatively be prepared from the compounds of formula II by reacting a compound of formula II with an aqueous acid, such as, for example, aqueous acetic acid.

[0045] One skilled in the art would recognize variations in the sequence and would recognize variations in the appropriate reaction conditions from the analogous reactions shown or otherwise known that may be appropriately used in the above-described processes to make the compounds of formulas I and II herein.

[0046] The products of the reactions described herein are isolated by conventional means such as extraction, distillation, chromatography, and the like.

[0047] Pharmaceutically acceptable acid addition salts of the compounds suitable for use in methods of the invention include salts derived from nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate, n-methyl glutamine, etc. (see, e.g., Berge et al., J. Pharmaceutical Science, 66: 1-19 (1977).

[0048] The acid addition salts of the basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner. The free base form may be regenerated by contacting the salt form with a base and isolating the free base in the conventional manner. The free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base for purposes of the present invention.

[0049] A physician or veterinarian of ordinary skill readily determines a subject who is exhibiting symptoms of any one or more of the diseases described above. Regardless of the route of administration selected, the compounds suitable for use in methods of the invention are formulated into pharmaceutically acceptable unit dosage forms by conventional methods known to the pharmaceutical art. An effective but nontoxic quantity of the compound is employed in treatment. The compounds can be administered in enteral unit dosage forms, such as, for example, tablets, sustained release tablets, enteric coated tablets, capsules, sustained release capsules, enteric coated capsules, pills, powders, granules, solutions, and the like. They may also be administered parenterally, such as, for example, subcutaneously, intramuscularly, intradermally, intramammarally, intravenously, and other administrative methods known in the art.

[0050] Although it is possible for a compound suitable for use in methods of the invention to be administered alone in a unit dosage form, preferably the compound is administered in admixture as a pharmaceutical composition suitable for use in methods of the invention. A pharmaceutical composition comprises a pharmaceutically acceptable carrier and a compound. A pharmaceutically acceptable carrier includes, but is not limited to, physiological saline, ringers, phosphate buffered saline, and other carriers known in the art. Pharmaceutical compositions may also include additives, for example, stabilizers, antioxidants, colorants, excipients, binders, thickeners, dispersing agents, readsorpotion enhancers, buffers, surfactants, preservatives, emulsifiers, isotonizing agents, and diluents. Pharmaceutically acceptable carriers and additives are chosen such that side effects from the pharmaceutical compound are minimized and the performance of the compound is not canceled or inhibited to such an extent that treatment is ineffective.

[0051] Methods of preparing pharmaceutical compositions containing a pharmaceutically acceptable carrier and a compound suitable for use in methods of the invention are known to those of skill in the art. All methods may include the step of bringing the compound in association with the carrier and additives. In general, the formulations are prepared by uniformly and intimately bringing the compound of the invention into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired unit dosage form.

[0052] The ordinarily skilled physician or veterinarian will readily determine and prescribe the therapeutically effective amount of the compound to treat the disease for which treatment is administered. In so proceeding, the physician or veterinarian could employ relatively low dosages at first, subsequently increasing the dose until a maximum response is obtained. Typically, the particular disease, the severity of the disease, the compound to be administered, the route of administration, and the characteristics of the mammal to be treated, for example, age, sex, and weight, are considered in determining the effective amount to administer. Generally, a therapeutically effective amount of a compound to treat diabetes mellitus and related conditions and symptoms is in a range of about 0.1-100 mg/kg of a patient's body weight, more preferably in the range of about 0.5-50 mg/kg of a patient's body weight, per daily dose. The compound may be administered for periods of short and long duration.

[0053] A therapeutically effective amount of a compound for treating diabetes mellitus and related conditions and symptoms can be administered prior to, concurrently with, or after the onset of the disease or symptom. The compound can be administered to treat diabetes mellitus type I, diabetes mellitus type II, or obesity. Preferably, the compound can be administered to treat damage to blood vessels, eyes, kidneys, nerves, autonomic nervous system, skin, connective tissue, or immune system. Still preferably, the compound can be administered to treat insulin resistance or hyperinsulinemia. Also preferably, the compound can be administered to treat diabetes-induced hypertension.

[0054] Moreover, the compound may be administered concurrently with insulin and/or a hypoglycemic compound to treat diabetes mellitus and related conditions and symptoms. The compound can be administered concurrently with insulin and/or a hypoglycemic compound to treat type I diabetes, type II diabetes, or obesity. Preferably, the compound can be administered concurrently with insulin and/or hypoglycemic compound to treat damage to blood vessels, eyes, kidneys, nerves, autonomic nervous system, skin, connective tissue, or immune system. Still preferably, the compound can be administered concurrently with insulin and/or hypoglycemic compound to treat insulin resistance or hyperinsulinemia. Also preferably, the compound can be administered concurrently with insulin and/or hypoglycemic compound to treat diabetes-induced hypertension.

[0055] Typically, a compound may be administered concurrently with insulin to treat type I diabetes, type II diabetes, and related conditions and symptoms. For type II diabetes, insulin resistance, hyperinsulinemia, diabetes-induced hypertension, obesity, or damage to blood vessels, eyes, kidneys, nerves, autonomic nervous system, skin, connective tissue, or immune system, a compound may be administered concurrently with a hypoglycemic compound instead of insulin. Alternatively, a compound may be administered concurrently with insulin and a hypoglycemic compound to treat type II diabetes, insulin resistance, hyperinsulinemia, diabetes-induced hypertension, obesity, or damage to blood vessels, eyes, kidneys, nerves, autonomic nervous system, skin, connective tissue, or immune system.

[0056] “Concurrent administration” and “concurrently administering” as used herein includes administering a compound suitable for use in methods of the invention and insulin and/or a hypoglycemic compound in admixture, such as, for example, in a pharmaceutical composition, or as separate compounds, such as, for example, separate pharmaceutical compositions administered consecutively, simultaneously, or at different times. Preferably, if the compound and insulin and/or hypoglycemic compound are administered separately, they are not administered so distant in time from each other that the compound and the insulin and/or hypoglycemic compound cannot interact and a lower dosage amount of insulin and/or hypoglycemic compound cannot be administered.

[0057] Suitable hypoglycemic compounds include, for example, metformin, acarbose, acetohexamide, glimepiride, tolazamide, glipizide, glyburide, tolbutamide, chlorpropamide, thiazolidinediones, alpha glucosidase inhibitors, biguanindine derivatives, and troglitazone, and a mixture thereof. Preferably, the hypoglycemic compound is tolbutamide.

[0058] A physician or veterinarian of ordinary skill readily determines a subject who is exhibiting symptoms of diabetes mellitus and related conditions and symptoms. Regardless of the route of administration selected, the compound and the insulin and/or hypoglycemic compound are formulated into pharmaceutically acceptable unit dosage forms by conventional methods known to the pharmaceutical art. An effective but nontoxic quantity of the compound and the insulin and/or hypoglycemic compound is employed in the treatment of diabetes mellitus and related conditions and symptoms. The compound and the insulin may be concurrently administered parenterally in admixture or may be concurrently administered enterally and/or parenterally separately. Similarly, the compound and the hypoglycemic compound may be concurrently administered enterally in admixture or may be administered enterally and/or parenterally separately. In some instances, the compound may be concurrently administered with insulin and a hypoglycemic compound. Such administration would involve enteral and/or parenteral administration as described above.

[0059] Parenteral administration includes subcutaneous, intramuscular, intradermal, intramammary, intravenous, and other administrative methods known in the art. Enteral administration includes tablets, sustained release tablets, enteric coated tablets, capsules, sustained release capsules, enteric coated capsules, pills, powders, granules, solutions, and the like.

[0060] A pharmaceutical composition suitable for administration includes a pharmaceutically acceptable carrier and a compound suitable for use in methods of the invention and, optionally, insulin and/or a hypoglycemic compound. A pharmaceutically acceptable carrier includes, but is not limited to, physiological saline, ringers, phosphate buffered saline, and other carriers known in the art. Pharmaceutical compositions may also include stabilizers, antioxidants, colorants, and diluents. Pharmaceutically acceptable carriers and additives are chosen such that side effects from the pharmaceutical compound are minimized and the performance of the compound is not canceled or inhibited to such an extent that treatment is ineffective.

[0061] Methods of preparing pharmaceutical compositions containing a pharmaceutically acceptable carrier and a compound suitable for use in methods of the invention and, optionally, insulin and/or a hypoglycemic compound, are known to those of skill in the art. All methods may include the step of bringing the compound and, optionally, a hypoglycemic compound in association with the carrier or additives. In general, the formulations are prepared by uniformly and intimately bringing the compound into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired unit dosage form.

[0062] The ordinarily skilled physician or veterinarian will readily determine and prescribe the therapeutically effective amount of the compound to treat the disease for which treatment is administered as described above.

[0063] When concurrently administering a compound with insulin and/or a hypoglycemic compound, the compound is administered in a range of about 0.1-100 mg per daily dose, typically 0.5-50 mg/kg of body weight per daily dose. A hypoglycemic compound is administered in a range of about 1 to 300 mg per daily dose, typically 1 to 200 mg per daily dose. Insulin is typically administered in a range of about 0.1 to 2 units/kg of a patient's body weight per daily dose. A “unit” of insulin refers to that amount of insulin necessary to lower the blood-sugar level in a rabbit by 50% in 1 to 3 hours.

[0064] The invention is further elaborated by the representative examples as follows. Such examples are not meant to be limiting but only illustrative of the invention.

EXAMPLES

Example 1

Synthesis of Morpholine Pyridoxal-4,5-aminal (1-Morpholino-1,3-dihydro-7-hydroxy-6-methylfuro(3,4-c)pyridine)

[0065] A mixture of morpholine (20 g) and toluene (100 mL) was stirred and heated using an oil bath set to 100° C. for 15 minutes. Pyridoxal hydrochloride (10 g) was then added and the reaction mixture was stirred at 100° C. for two hours. The reaction mixture was then concentrated by distillation of the toluene and morpholine. The concentrated reaction mixture was washed three times by adding toluene (100 mL) and removing the toluene by distillation. After washing, the residue was dissolved in toluene and filtered, and then hexane was added until precipitation began, at which time the reaction mixture was left overnight at room temperature. Crystals were collected and washed thoroughly with hexane.

[0066] Nuclear magnetic resonance spectroscopy (NMR) and mass spectroscopy confirmed the identity of the synthesized compound. The purity of the compound was analyzed by high performance liquid chromatography (HPLC) using a C-18 reverse phase column and water/acetonitrile as solvent (1-100% acetonitrile over 25 minutes).

Example 2

Synthesis of the 3-Toluate of the Morpholine Pyridoxal-4,5-aminal (1-Morpholino-1,3-dihydro-7-(p-toluoyloxy)-6-methylfuro(3,4-c)pyridine)

[0067] Anhydrous powdered potassium carbonate (5 g), acetone (100 mL), and morpholine pyridoxal-4,5-aminal (1-morpholino-1,3-dihydro-7-hydroxy-6-methylfuro(3,4-c)pyridine) (1.11 g, 5 mmoles) were mixed in a nitrogen-cooled, dry flask. The reaction mixture was cooled to between 0 and 5° C. and then p-toluoyl chloride (1.06 g, 6 mmoles) in acetone (20 mL) was added. This mixture was stirred for two hours, followed by filtering out the solid and evaporating the solution to dryness under vacuum. The residue was chromatographed on silica gel using a mixture of ethyl acetate and hexane as solvent.

[0068] The purified solid was analyzed by thin layer chromatography (TLC), NMR, and mass spectroscopy. The purity of the synthesized compound was confirmed by HPLC as described in Example 1.

Example 3

Synthesis of the 3-Toluate of Pyridoxal (2-Methyl-3-toluoyloxy-4-formyl-5-hydroxymethylpyridine)

[0069] Anhydrous potassium carbonate (10 g), acetone (100 mL), and pyridoxal hydrochloride (2.03 g, 10 mmoles) were mixed in a nitrogen-cooled, dry flask. The mixture was cooled to between 0 and 5° C. and then p-toluoyl chloride (2.12 g, 12 mmoles) in acetone (2 mL) was added. The reaction mixture was stirred for two hours followed by filtering out the solid and evaporating the solution to dryness under vacuum. The residue was chromatographed on silica gel as described in Example 2.

[0070] The purified solid was analyzed by TLC, NMR, and mass spectroscopy. The purity of the compound was confirmed by HPLC as described in Example 1.

[0071] Alternative to the above-described method, the 3-toluate of pyridoxal is synthesized by reacting the compound of Example 2 with 80% aqueous acetic acid at 60° C. for 30 minutes, and then diluting with water and extracting by ethyl acetate. The ethyl acetate layer is washed with 5% aqueous sodium bicarbonate, dried with magnesium sulfate, and evaporated to dryness. The compound is also analyzed as described supra.

Example 4

Synthesis of 3β-Naphthoate of the Morpholine Pyridoxal-4,5-aminal (1-Morpholino-1,3-dihydro-7-(β-naphthoyloxy)-6-methylfuro(3,4-c)pyridine)

[0072] Anhydrous powdered potassium carbonate (5 g), acetone (100 mL), and morpholine pyridoxal-4,5-aminal (1-morpholino-1,3-dihydro-7-hydroxy-6-methylfuro(3,4-c)pyridine) (1.11 g, 5 mmoles) were mixed in a nitrogen-cooled, dry flask. The mixture was cooled to between 0 and 5° C. and then β-naphthoyl chloride (1.06 g, 6 mmoles) in acetone (20 mL) was added. The reaction mixture was stirred for two hours, and then the solid was filtered out and the solution was evaporated to dryness under vacuum. The residue was chromatographed according to Example 2.

[0073] The purified solid was analyzed according to Example 2, and the purity was confirmed according to Example 1.

Example 5

Synthesis of the 3β-Naphthoate of Pyridoxal (2-Methyl-3-β-naphthoyloxy-4-formyl-5-hydroxymethylpyridine)

[0074] Anhydrous potassium carbonate (10 g), acetone (100 mL), and pyridoxal hydrochloride (2.03 g, 10 mmoles) were mixed in a nitrogen-cooled, dry flask. The mixture was cooled to between 0 and 5° C. and then β-naphthoyl chloride (2.12 g, 12 mmoles) in acetone (2 mL) was added and the mixture was stirred for two hours. The solid was filtered out and the solution was evaporated to dryness under vacuum. The residue was chromatographed according to Example 2.

[0075] The purified solid was analyzed according to Example 2, and the purity was confirmed according to Example 1.

[0076] Alternative to the above-described synthesis, the 3-β-naphthoate of pyridoxal is prepared by reacting the compound of Example 4 with 80% aqueous acetic acid at 60° C. for 30 minutes, followed by diluting with water and extracting by ethyl acetate. The ethyl acetate layer is then washed with 5% aqueous sodium bicarbonate, dried with magnesium sulfate, and evaporated to dryness. The compound is also analyzed as described supra.

Example 6

Synthesis of 3-Pivaloyl of the Morpholine Pyridoxal-4,5-aminal (1-Morpholino-1,3-dihydro-7-pivaloyloxy)-6-methylfuro(3,4-c)pyridine)

[0077] Anhydrous powdered potassium carbonate (5 g), acetone (100 mL), and morpholine pyridoxal-4,5-aminal (1-morpholino-1,3-dihydro-7-hydroxy-6-methylfuro(3,4-c)pyridine) (1.11 g, 5 mmoles) were mixed in a nitrogen-cooled, dry flask. The mixture was cooled to between 0 and 5° C. and then pivaloyl chloride (trimethylacetyl chloride) (720mg, 6 mmoles) in acetone (20 mL) was added. The reaction mixture was stirred for two hours. The solid was then filtered out and the solution was evaporated to dryness under vacuum. The residue was chromatographed according to Example 2.

[0078] The purified solid was analyzed according to Example 2, and the purity was confirmed according to Example 1.

Example 7

Synthesis of 3-Dimethylcarbamoyl of the Morpholine Pyridoxal-4,5-aminal (1-Morpholino-1,3-dihydro-7-(dimethylcarbamoyloxy)-6-methylfuro(3,4-c)pyridine)

[0079] Anhydrous powdered potassium carbonate (5 g), acetone (100 mL), and morpholine pyridoxal-4,5-aminal (1-morpholino-1,3-dihydro-7-hydroxy-6-methylfuro(3,4-c)pyridine) (1.11 g, 5 mmoles) were mixed in a nitrogen-cooled, dry flask. The mixture was cooled to between 0 and 5° C. and then dimethylcarbamoyl chloride (642 mg, 6 mmoles) in acetone (2 mL) was added. The reaction mixture was stirred for two hours. The solid was then filtered out and the solution was evaporated to dryness under vacuum. The residue was chromatographed according to Example 2.

[0080] The purified solid was analyzed according to Example 2, and the purity was confirmed according to Example 1.

Example 8

Synthesis of 3-Acetylsalicyloyl of the Morpholine Pyridoxal-4,5-aminal (1-Morpholino-1,3-dihydro-7-acetylsalicyloxy)-6-methylfuro(3,4-c)pyridine)

[0081] Anhydrous powdered potassium carbonate (5 g), acetone (100 mL), and morpholine pyridoxal-4,5-aminal (1-morpholino-1,3-dihydro-7-hydroxy-6-methylfuro(3,4-c)pyridine) (1.11 g, 5 mmoles) were mixed in a nitrogen-cooled, dry flask. The mixture was cooled to between 0 and 5° C. and then acetylsalicyloyl chloride (1.09 g, 6 mmoles) in acetone (2 mL) was added. The reaction mixture was stirred for two hours. The solid was then filtered out and the solution was evaporated to dryness under vacuum. The residue was chromatographed according to Example 2.

[0082] The purified solid was analyzed according to Example 2, and the purity was confirmed according to Example 1.

[0083] It should be noted that, as used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to a composition containing “a compound” includes a mixture of two or more compounds. Similarly, reference to “a compound” includes a mixture having more than one compound.

[0084] Although embodiments of the invention have been described above, it is not limited thereto, and it will be apparent to persons skilled in the art that numerous modifications and variations form part of the present invention insofar as they do not depart from the spirit, nature, and scope of the claimed and described invention.

Claims

Post-issuance certificates present

The text shown below may not reflect later post-issuance changes.

We claim:

1. A method of treating diabetes mellitus in a mammal comprising: administering to the mammal a therapeutically effective amount of a 3-acylated pyricoxal analogue or a pharmaceutically acceptable acid addition salt thereof.

2. A method according to claim 1, wherein the diabetes mellitus treated is insulin-dependent diabetes mellitus.

3. A method according to claim 1, wherein the diabetes mellitus treated is noninsulin-dependent diabetes mellitus.

4. A method according to claim 1, wherein the 3-acylated pyridoxal analogue is a compound of the formula

wherein

R₁is a straight or branched alkyl group, a straight or branched alkenyl group, in which an alkyl or alkenyl group may be interrupted by a nitrogen or oxygen atom; an alkoxy group; a dialkylamino group; or an unsubstituted or substituted aryl group.

5. A method according to claim 4, wherein R₁is phenyl or naphthyl in which phenyl or naphthyl is unsubstituted or substituted by an alkyl group of 1 to 4 carbon atoms, an alkoxy group of 1 to 4 carbon atoms, an amino group, a hydroxy group, or an acetyloxy group.

6. A method according to claim 4, wherein the 3-acylated pyridoxal analogue is 2-methyl-3-toluoyloxy-4-formyl-5-hydroxymethylpyridine.

7. A method according to claim 4, wherein the 3-acylated pyridoxal analogue is 2-methyl-3-βnaphthoyloxy-4-formyl-5-hydroxymethylpyridine.

8. A method according to claim 1, wherein the 3-acylated pyridoxal analogue is a compound of the formula

wherein

R₂is a secondary amino group.

9. A method according to claim 8, wherein R₁is an alkyl group; an alkoxy group; a dialkylamino group; or phenyl or naphthyl in which phenyl or naphthyl is unsubstituted or substituted by an alkyl group of 1 to 4 carbon atoms, an alkoxy group of 1 to 4 carbon atoms, an amino group, a hydroxy group, or an acetyloxy group.

10. A method according to claim 8, wherein R₂is a group of the formula

wherein R₃and R₄are each independently alkyl or when taken together form a ring with the nitrogen atom and which ring may optionally be interrupted by a nitrogen or oxygen atom.

11. A method according to claim 8, wherein the 3-acylated pyridoxal analogue is 1-morpholino-1,3-dihydro-7-(p-toluoyloxy)-6-methylfuro(3,4-c)pyridine.

12. A method according to claim 8, wherein the 3-acylated pyridoxal analogue is 1-morpholino-1,3-dihydro-7-(β-naphthoyloxy)-6-methylfuro(3,4-c)pyridine.

13. A method according to claim 8, wherein the 3-acylated pyridoxal analogue is 1-morpholino-1,3-dihydro-7-pivaloyloxy-6-methylfuro(3,4-c)pyridine.

14. A method according to claim 8, wherein the 3-acylated pyridoxal analogue is 1-morpholino-1,3-dihydro-7-(dimethylcarbamoyloxy-6-methylfuro(3,4-c)pyridine.

15. A method according to claim 8, wherein the 3-acylated pyridoxal analogue is 1-morpholino-1,3-dihydro-7-acetylsalicyloxy-6-methylfuro(3,4-c)pyridine.

16. A method according to claim 1, wherein the compound is administered enterally or parenterally.

17. A method according to claim 1, wherein the therapeutically effective amount is in a range of about 0.5-100 mg/kg of the mammal's body weight per day.

18. A method of treating diabetes mellitus in a mammal comprising: administering to the mammal a therapeutically effective amount of a compound selected from the group consisting of pyridoxamine, pyridoxal, pyidoxine, a pharmaceutically acceptable acid addition salt thereof, and a mixture thereof.

19. A method according to claim 18, wherein the diabetes mellitus treated is insulin-dependent diabetes mellitus.

20. A method according to claim 18, wherein the diabetes mellitus treated is noninsulin-dependent diabetes mellitus.

Patent Citations (104)

Patent	Date	Inventor	Cited By
US3206463(A)	1965-09-01	Baetz	Applicant
US3910921(A)	1975-10-01	Esanu	Applicant
US3987177(A)	1976-10-01	Giudicelli et al.	Applicant
US4032534(A)	1977-06-01	Chodkiewicz	Applicant
US4036844(A)	1977-07-01	Thorne et al.	Applicant
US4053607(A)	1977-10-01	Thorne et al.	Applicant
US4137316(A)	1979-01-01	Esanu	Applicant
US4167562(A)	1979-09-01	Evers	Applicant
US4361570(A)	1982-11-01	Fici	Applicant
US4369172(A)	1983-01-01	Schor et al.	Applicant
US4374841(A)	1983-02-01	Descamps et al.	Applicant
US4515771(A)	1985-05-01	Fine	Applicant
US4567179(A)	1986-01-01	Lombardino	Applicant
US4569938(A)	1986-02-01	Esanu	Applicant
US4569939(A)	1986-02-01	Esanu	Applicant
US4581363(A)	1986-04-01	Esanu	Applicant
US4605741(A)	1986-08-01	Zagnoli et al.	Applicant
US4730042(A)	1988-03-01	Hege et al.	Applicant
US4735950(A)	1988-04-01	Esanu	Applicant
US4735956(A)	1988-04-01	Baldwin et al.	Applicant
US4837239(A)	1989-06-01	Benjamin et al.	Applicant
US4843071(A)	1989-06-01	Hohenwarter	Applicant
US4962121(A)	1990-10-01	Hamberger et al.	Applicant
US5001115(A)	1991-03-01	Sloan	Applicant
US5053396(A)	1991-10-01	Blass	Applicant
US5118505(A)	1992-06-01	Költringer	Applicant
US5130324(A)	1992-07-01	Ulrich et al.	Applicant
US5132115(A)	1992-07-01	Wolter et al.	Applicant
US5210083(A)	1993-05-01	Pfirrmann	Applicant
US5213813(A)	1993-05-01	Kornecki et al.	Applicant
US5254557(A)	1993-10-01	Buckle et al.	Applicant
US5254572(A)	1993-10-01	Serfontein	Applicant
US5272165(A)	1993-12-01	Ulrich et al.	Applicant
US5278154(A)	1994-01-01	Lacoste et al.	Applicant
US5288716(A)	1994-02-01	Speck	Applicant
US5326757(A)	1994-07-01	Demopoulos	Applicant
US5328453(A)	1994-07-01	Sibalis	Applicant
US5372999(A)	1994-12-01	Schneider et al.	Applicant
US5385937(A)	1995-01-01	Stamler et al.	Applicant
US5420112(A)	1995-05-01	Lewis et al.	Applicant
US5441972(A)	1995-08-01	Ogata et al.	Applicant
US5504090(A)	1996-04-01	Neely	Applicant
US5563126(A)	1996-10-01	Allen et al.	Applicant
US5569459(A)	1996-10-01	Shlyankevich	Applicant
US5569648(A)	1996-10-01	Lewis et al.	Applicant
US5631271(A)	1997-05-01	Serfontein	Applicant
US5633228(A)	1997-05-01	Lewis et al.	Applicant
US5648335(A)	1997-07-01	Lewis et al.	Applicant
US5728684(A)	1998-03-01	Cheng et al.	Applicant
US5733884(A)	1998-03-01	Barbul et al.	Applicant
US5733916(A)	1998-03-01	Neely	Applicant
US5770215(A)	1998-06-01	Moshyedi	Applicant
US5795873(A)	1998-08-01	Allen	Applicant
US5804163(A)	1998-09-01	Gibby et al.	Applicant
US5804594(A)	1998-09-01	Murad	Applicant
US5833998(A)	1998-11-01	Biedermann et al.	Applicant
US5834446(A)	1998-11-01	Dow et al.	Applicant
US5840685(A)	1998-11-01	Fujii et al.	Applicant
US5847008(A)	1998-12-01	Doebber et al.	Applicant
US5858017(A)	1999-01-01	Demopulos et al.	Applicant
US5859051(A)	1999-01-01	Adams et al.	Applicant
US5874420(A)	1999-02-01	Pelleg	Applicant
US5874443(A)	1999-02-01	Kiely et al.	Applicant
US5888514(A)	1999-03-01	Weisman	Applicant
US6043259(A)	2000-03-01	Dhalla et al.	Examiner
US6051587(A)	2000-04-01	Dakashinamurti et al.	Examiner
US6103748(A)	2000-08-01	Bryan	Examiner
US6274612(B1)	2001-08-01	Bryan	Examiner
BE831350	1976-01-01		Applicant
BE863754	1978-05-01		Applicant
CH561183	1975-04-01		Applicant
DE1958226	1970-05-01		Applicant
DE2461742	1976-07-01		Applicant
DE3705549	1988-09-01		Applicant
DE4344751	1995-06-01		Applicant
EP121036	1984-10-01		Applicant
EP144051	1985-06-01		Applicant
EP270026	1988-06-01		Applicant
EP416248	1991-03-01		Applicant
EP891719	1999-01-01		Applicant
FR846376	1941-03-01		Applicant
FR1323941	1963-12-01		Applicant
FR5552	1967-12-01		Applicant
FR5.801	1968-03-01		Applicant
FR6453	1968-12-01		Applicant
FR1579544	1969-08-01		Applicant
FR2034539	1970-12-01		Applicant
FR2101010	1972-03-01		Applicant
FR2255883	1975-07-01		Applicant
FR2428640	1980-01-01		Applicant
GB1013939	1965-12-01		Applicant
GB1201014	1970-08-01		Applicant
GB1297080	1972-11-01		Applicant
GB1360536	1974-07-01		Applicant
GB1493993	1977-12-01		Applicant
GB1597428	1981-09-01		Applicant
GB2254556	1992-10-01		Applicant
JP48-21959	1973-07-01		Applicant
JP54-17130	1979-02-01		Applicant
WO83/00085	1983-01-01		Applicant
WO91/19500	1991-12-01		Applicant
WO94/18965	1994-09-01		Applicant
WO99/03365	1999-01-01		Applicant
WO99/53928	1999-10-01		Applicant

Non-Patent Literature (49)

Boll, Walter; et al., “Vitamin B6: Eine Neue Synthese Durch Diels-Alder-Reaktion”; Liebigs Annalen der Chemie, 1979, pp. 1657-1664.Applicant
Hayakawa, M.; et al. “The In Vitro and In Vivo Inhibition of Protein Glycosylation and Diabetic Vascular Basement Membrane Thickening by Pyridoxal-5′-Phosphate”; Journal of Nutritional Science and Vitaminology, vol. 37(2), Apr. 1991, pp. 149-159.Applicant
Nair, A.R.; et al. “Effect of Pyridoxine and Insulin Administration on Brain Glutamate Dehydrogenase Activity and Blood Glucose Control in Streptozotocin-Induced Diabetic Rats”; Biochimica et Biophysica Acta, vol. 1381(3), Aug. 24, 1998, pp. 351-354.Applicant
Onorato, J.M.; et al. “Pyrodoxamine, An Inhibitor of Advanced Glycation Reactions, Also Inhibits Advanced Lipoxidation Reactions”; The Journal of Biological Chemistry, vol. 275(28), Jul. 14, 2000, pp. 21177-21184.Applicant
Pasechnik, I.; “Effect of pyridoxine on blood sugar levels in normal conditions and in experimental hyperglycemia”, Voprosy Pitaniia (USSR), May-Jun. 1971: 30(3): 44-6 [article in Russian: English Abstract provided].Applicant
Sasaki, Hideo; et al.; “Effect of Pyridoxal Phosphate on the Carbohydrate and Lipid Metabolism of the Patient With Diabetes Mellitus”; Niigata Medical Journal, vol. 85 (3), 1971, pp. 163-169 [article in Japanese; English Abstract provided].Applicant
Yamagata, S.; et al. “Therapeutic Effects of Pyridoxal Phosphate on Diabetic Neuropathy”; Bitamin, vol. 35(6), 1967, pp. 485-493 [Article in Japanese; English Abstract provided].Applicant
Aybak, M. et al., “Effect of Oral Pyridoxine Hydrochloride Supplementation on Arterial Blood Pressure in Patients with Essential Hypertension”, Drug Res., vol. 45, No. 12, pp. 1271-1273 (1995).Applicant
Baliga, B. et al., “Hyperhomocysteinemia in Type 2 Diabetes Mellitus: Cardiovascular Risk Factors and Effect of Treatment with Folic Acid and Pyridoxine”, Endocrine Practice, vol. 6, No. 6, pp. 435-441 (Nov./Dec. 2000).Applicant
Bhagavan, H. et al., “Effect of Postweanling Pyridoxine Deficiency on Growth and Concentration of the Coenzyme Pyridoxal-5′-phosphate in Heart, Kidneys, Lungs, and Adrenals in Rats”, Pediat. Res., vol. 10, pp. 730-732 (1976).Applicant
Folsom, A. et al., “Clinical Investigation and Reports: Prospective Study of Coronary Heart Disease Incidence in Relation to Fasting Total Homosysteine, Related Genetic Polymorphisms, and B Vitamins: The Atherosclerosis Risk in Communities (ARIC) Study”, Circulation, vol. 98, pp. 204-210 (Jul. 21, 1998).Applicant
Kubyshkin, V. et al., “Comparative characteristics of the arrhythmic syndrome and the possibility for its coenzyme correction in dilated and hypertrophic cardiomyopathy”, Abstract, 1 p. (1989).Applicant
Levy, H. et al., “Pyridoxine Deficiency in Congestive Heart Failure”, P.S.E.B.M., vol. 101, pp. 617-621 (1959).Applicant
Manore, M. et al., “Changes In Plasma Pyridoxal Phosphate (PLP) In Diabetic (D), Hypertensive (HTN) and Hypertensive-diabetic (HTN-D) Men Fed A Constant Vitamin B-6 (B6) Diet”, Source Unknown, pp. 1254 (Date Unknown).Applicant
Mendelsohn, A. et al., “Hemodynamic and Clinical Effects of Oral Levodopa in Children With Congestive Heart Failure”, JACC, vol. 30, No. 1, pp. 237-242 (Jul. 1997).Applicant
Mulvaney, D. et al., “Electrocardiographic changes in vitamin B6 deficient rats”, Cardiovascular Research, vol. 13, pp. 506-513 (1979).Applicant
Rao, R. et al., “Failure of Pyridoxine to Improve Glucose Tolerance in Diabetics”, Journal of Clinical Endocrinology & Metabolism, vol. 50, No. 1, pp. 198-200 (Jan. 1980).Applicant
Takuma, Y. et al, “Combination Therapy of Infantile Spasms With High-Dose Pyridoxal Phosphate and Low-Dose Corticotropin”, Journal of Child Neurology, vol. 11, No. 1, pp. 35-40 (Jan. 1996).Applicant
Vidrio, H., “Interaction with Pyridoxal as a Possible Mechanism of Hydralazine Hypotension”, Journal of Cardiovascular Pharmacology, vol. 15, pp. 150-156 (1990).Applicant
Yarat, A. et al., “Effect of vitamin B6 on lenses of diabetic rats”, Indian Journal of Experimental Biology, vol. 36, pp. 1269-1272 (Dec. 1998).Applicant
“B Vitamins May Cut Heart Disease Risk”, Harvard Health Letter, 1 page (1998).Applicant
Barrett, S., “Homocysteine: A Cardiovascular Risk Factor Worth Considering”, http://www.quackwatch.com/03HealthPromotion/homocysteine.html, 2 pages (©1997).Applicant
Bernstein, A., “Vitamin B6 in Clinical Neurology”, Annals of New York Academy of Sciences, vol. 585, pp. 250-260 (1990).Applicant
Berger, A.R. et al., “Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: A prospective study of pyridoxine neurotoxicity”, Neurology, vol. 42, No. 7, pp. 1367-1370 (Jul. 1992).Applicant
Bode, W. et al., “Pyridoxal-5′-Phosphate and Pyridoxal Biokinetics in Male Wistar Rats Fed Graded Levels of Vitamin B-6”, J. Nutr., vol. 121, No. 11, pp. 1738-1745 (Nov. 1991).Applicant
Chasan-Taber, L. et al., “A Prospective Study of Folate and Vitamin B6 and Risk of Myocardial Infarction in US Physicians”, Journal of the American College of Nutrition, vol. 15, No. 2, pp. 136-143 (Apr. 1996).Applicant
Cho, Y. et al., “In Vivo Evidence for a Vitamin B-6 Requirement in Carnitine Synthesis”, J. Nutr., vol. 120, pp. 258-265 (1990).Applicant
“Computer Generated Search Reports”, 70 pages (May 1999).Applicant
Ellis, J. et al., “Prevention of Myocardial Infarction by Vitamin B6 ”, Res. Commun. Molec. Pathol. Pharmacol., vol. 89, No. 2, pp. 208-220 (Aug. 1995).Applicant
Harada, K. et al., “Studies on Vitamin B6. (IV) Behavior of Pyridoxal Acylates in the Body After Parenteral Administration”, Vitamins Journal of the Vitamin Society of Japan, vol. 45, No. 2, pp. 69-75 (Feb. 1972).Applicant
Hoover, D.M. et al., “Ultrastructural Lesions of Pyridoxine Toxicity in Beagle Dogs”, Vet. Pathol., vol. 18, pp. 769-777 (1981).Applicant
Kok, F. et al., “Low Vitamin B6 Status in Patients with Acute Myocardial Infarction”, Am. J. Cardiol., vol. 63, pp. 513-516 (Mar. 1, 1989).Applicant
Korytnyk et al. Schiff Bases of Pyridoxal: Their Structure and the Stabilization of their Ring-Chain Tautomeric Forms by Acylation, Tetrahedron, 26 (23), 5415-25.Applicant
Krinke, G. et al., “Pyridoxine Megavitaminosis: An Analysis of the Early Changes Induced with Massive Doses of Vitamin B6 in Rat Primary Sensory Neurons”, J. Neuropathol. Exp. Neurol., vol. 44, No. 7, pp. 117-129 (Mar. 1985).Applicant
Lal, K. et al., “Hypotensive action of 5-HT receptor agonists in the vitamin B6-deficient hypertensive rat”, Eur. J. Pharmacol., vol. 234, Nos. 2/3, pp. 183-189 (Apr. 1993).Applicant
Lal, K. et al., “Calcium channels in vitamin B6 deficiency-induced hypertension”, Journal of Hypertension, vol. 11, No. 12, pp. 1357-1362 (Dec. 1993).Applicant
Lal, K. et al., “The effect of vitamin B6 on the systolic blood pressure of rats in various animal models of hypertension”, Journal of Hypertension, vol. 14, No. 3, pp. 355-363 (Mar. 1996).Applicant
Merrill, Jr. et al. A. et al., “Diseases associated with defects in vitamin B6 metabolism or utilization”, Ann. Rev. Nutr., vol. 7, pp. 137-156 (1987).Applicant
Omenn, G. et al., “Preventing Coronary Heart Disease”, Circulation, vol. 97, pp. 421-424 (1998).Applicant
Paulose, C. et al., “Sympathetic Stimulation and Hypertension in the Pyridoxine-Deficient Adult Rat”, Hypertension, vol. 11, No. 4, pp. 387-391 (Apr. 1988).Applicant
Rimm, E. et al., “Folate and Vitamin B6 From Diet and Supplements in Relation to Risk of Coronary Heart Disease Among Women”, JAMA, vol. 279, No. 5, pp. 359-364 (Feb. 4, 1998).Applicant
Sakuragi, T. et al., “The Synthesis of Long Chain Fatty Acid Derivatives of the Vitamin B6 Group”, J. Am. Chem. Soc., vol. 78, pp. 839-842 (Feb. 20, 1956).Applicant
Tanaka, T. et al., “Pyridoxine Derivatives”, Chemical Abstracts, vol. 62, No. 12, 1 page (Jun. 7, 1965).Applicant
Trezise, D. et al., “P2 purinoceptor antagonist properties of pyridoxal-5-phosphate”, Eur. J. Pharmacol., vol. 259, No. 3, pp. 295-300 (Jul. 11, 1994).Applicant
Verhoef, P. et al., “Homocysteine Metabolism and Risk of Myocardial Infarction: Relation with Vitamins B6, B12, and Folate”, Am. J. Epidemiol., vol. 143, No. 9, pp. 845-859 (May 1, 1996).Applicant
Vermaak, W.J.H. et al., “Vitamin B6 and coronary artery disease. Epidemiological observations and case studies”, Atherosclerosis, vol. 63, pp. 235-238 (Feb. 1987).Applicant
Viscontini, V. et al., “Über einige Derivate des Pyridoxals”, Helvetica Chimica Acta, vol. 34, No. 296, pp. 2438-2439 (1951).Applicant
Windebank, A., “Neurotoxicity of Pyridoxine Analogs Is Related to Coenzyme Structure”, Neurochemical Pathology, vol. 3, pp. 159-167 (1985).Applicant
Zempleni, J. et al., “The utilization of intravenously infused pyridoxine in humans”, Clinica Chimica Acta, vol. 229, Nos. 1, 2, pp. 27-36 (Sep. 1994).Applicant

Abstract